Jiangsu Hengrui Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Jiangsu Hengrui Pharmaceuticals Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Jiangsu Hengrui Pharmaceuticals Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Jiangsu Hengrui Pharmaceuticals Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Jiangsu Hengrui Pharmaceuticals Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany, Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu, China.
Headquarters
China
Address
No.7 Kunlunshan Road, Lianyungang Eco & Tech Development Zone, Jiangsu, 222000
Website
www.hengrui.com
Telephone
86 216 1053323
No of Employees
20,602
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600276 (SHA)
Revenue (2024)
$4.4B
13%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
21.7%
(2024 vs 2023)
Market Cap*
$50.5B
Net Profit Margin (2024)
XYZ
7.7%
(2024 vs 2023)
* As of and is in US$
Jiangsu Hengrui Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Antitumor Drugs: | Supply and Distribution | EyeSol |
| Apatini Tablets | Interventional Imaging Solutions | Callispheres |
| Pemen Dong Enzyme Injection | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company partnered with GSK to develop up to 12 innovative medicines across the Respiratory, Immunology & Inflammation, and Oncology pipeline. |
| 2025 | Acquisitions/Mergers/Takeovers | In January, the company acquired Shandong Ruiyuan Pharmaceutical Co., Ltd. |
| 2024 | Contracts/Agreements | In July, the company signed an agreement with CStone Pharmaceuticals to permit the exclusive promotion rights of precision therapy AYVAKIT (avapritinib tablets) in mainland China. |
Competitor Comparison
| Key Parameters | Jiangsu Hengrui Pharmaceuticals Co Ltd | Sinopharm Group Co Ltd | Sino Biopharmaceutical Ltd | Akeso Inc | Chongqing Laimei Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Lianyungang | Shanghai | Hong Kong City | Zhongshan | Chongqing |
| State/Province | Jiangsu | Shanghai | - | Guangdong | Chongqing |
| No. of Employees | 20,602 | 94,910 | 24,379 | 3,761 | 973 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sun Piaoyang | Chairman | Executive Board | 2021 | 67 |
| Feng Ji | Chief Operating Officer; Director; President | Executive Board | 2025 | 55 |
| Dai Hongbin | Vice Chairman | Executive Board | 2025 | 49 |
| Jiangning Army | Executive Vice President; Director | Executive Board | 2024 | 65 |
| Zhang Lianshan | Director; Executive Vice President | Executive Board | 2024 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer